MUMuhammad Uzair

Muhammad Uzair

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Uzair has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regional vs. Local Anesthesia for Arteriovenous Fistula Creation in Adults With End‐Stage Kidney Disease: A Grade Assessed Systematic Review and Meta‐Analysis

    by Hammad Saif, Salar Khan, Muhammad Shahzaib, Syed Muhammad Rayyan, Muhammad Uzair, Mueed Iqbal, Bakhtiyar Ameer, Hira Shehzad, Sarmad Nazir, Abdur Rehman Noor

    Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis in patients with end‐stage renal disease (ESRD), yet high rates of primary failure and suboptimal patency remain significant challenges. The choice of anesthetic technique may influence vascular dynamics and AVF outcomes. This study aims to compare the effectiveness of regional anesthesia (RA) versus local anesthesia (LA) on clinical outcomes following AVF creation in adults with ESRD. A systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed, Cochrane Library, Scopus, and ClinicalTrials.gov were searched from inception to November 2025. Randomized controlled trials and comparative observational studies evaluating RA versus LA in adult AVF creation were included. Primary outcomes included primary patency, functional patency, and primary failure rate. Secondary outcomes included complications, re‐interventions, anesthesia time, and vascular parameters. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were pooled using a random‐effects model where appropriate. Ten studies involving 1920 patients (RA: 949; LA: 971) were included. RA was associated with significantly higher primary patency (RR = 0.93; 95% CI: 0.87–0.98; p = 0.01) and lower primary failure rates (RR = 1.47; 95% CI: 1.00–2.16; p = 0.05). Complications (RR = 1.49; p = 0.03) and re‐interventions (RR = 2.28; p = 0.03) were significantly higher in the LA group. No significant differences were observed in functional patency, anesthesia time, or brachial artery diameter. RA is associated with improved early AVF outcomes, including higher primary patency and reduced failure, complications, and re‐interventions, without increasing operative time. These findings suggest that RA may improve early AVF outcomes in selected settings where expertise and resources are available.

  • Clarifying the role of METTL1-associated m7G modification in acute kidney injury

    by Syed Huzaifa Khan, Syed Muhammad Rayyan, Touqeer Rehman, Hunain Shahbaz, Muhammad Uzair


  • Open Access

    Methodological Considerations in the Pilot Study of a Novel Transcutaneous Peripheral Nerve Stimulation System for Essential Tremor

    by Muhammad Uzair

    I read with great interest the pilot study by Richard Dewey III, et al., investigating a novel transcutaneous peripheral nerve stimulation (TPNS) system for essential tremor (ET) [1]. The reported improvements in TETRAS scores are indeed striking. The development of non-invasive neuromodulation therapies is a valuable contribution to the ET treatment landscape. However, the open-label, uncontrolled design of the study necessitates a cautious interpretation of the results, as the potential for placebo and expectation effects to influence the outcomes is considerable and merits further discussion. First, the inclusion criteria required the participants to be proficient with smartphones and Wi-Fi. This may have created a selection bias toward a more technologically adept and potentially younger patient population. This significantly limits the generalizability of the findings to the wider ET community, which includes a substantial proportion of older individuals who may not possess these digital literacy skills yet represent a core demographic for whom new treatments are desperately needed. Second, the intervention period was limited to 7-10 days. This duration is insufficient to evaluate the sustainability of the therapeutic effect, long-term patient adherence, or the potential for lateonset adverse events. For a chronic condition like ET and a device intended for prolonged daily use, data on efficacy and safety beyond the short-term novelty effect are crucial [2]. Finally, the primary outcome measures-TETRAS Activities of Daily Living (ADL), Performance scores, and Global Impression of Change questionnaires (PGI-I/CGI-I)-are inherently subjective. The absence of blinding in patients and investigators leaves these endpoints highly vulnerable to expectation bias. The concordance in improvement rates on the PGI-I and CGI-I (82%) is consistent with a shared positive bias rather than definitive evidence of efficacy. Although the authors acknowledge the lack of a sham control, the probable magnitude of this confound and its likely contribution to the effect size were not explored. The advanced technological nature of the intervention ("AI-powered," "novel") may further potentiate a placebo response. We acknowledge that the authors have a larger, sham-controlled trial underway (NCT06235190), which will be crucial in addressing these critical methodological concerns. Until the results of that rigorous trial are available, the results of this pilot study should be viewed as